Basit öğe kaydını göster

Reduced Serum sRANKL and sTREM2 Levels in High-Grade Gliomas: Association with Prognosis

dc.contributor.authorSanli, Elif
dc.contributor.authorBalak, Naci
dc.contributor.authorTurkoglu, Ceren
dc.contributor.authorEfendioglu, Mustafa
dc.date.accessioned2021-12-10T11:35:50Z
dc.date.available2021-12-10T11:35:50Z
dc.date.issued2021
dc.identifier.citationEfendioglu M., Sanli E., Turkoglu C., Balak N., "Reduced Serum sRANKL and sTREM2 Levels in High-Grade Gliomas: Association with Prognosis", NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.58, sa.2, ss.133-136, 2021
dc.identifier.issn1300-0667
dc.identifier.otherav_8827e4db-3b6a-477b-8300-ea63f49634d0
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/172212
dc.identifier.urihttps://doi.org/10.29399/npa.27536
dc.description.abstractIntroduction: High-grade gliomas (HGG), including Glioblastoma multiforme (GBM), account for the majority of primary brain tumors. Nevertheless, prognostic and diagnostic biomarkers are quite limited for HGG. The objective of this study was to investigate the prognostic value of sRANKL and sTREM2 levels in HGG patients.
dc.language.isoeng
dc.subjectNeurology (clinical)
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectDahili Tıp Bilimleri
dc.subjectNeurology
dc.subjectNöroloji
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectKLİNİK NEUROLOJİ
dc.titleReduced Serum sRANKL and sTREM2 Levels in High-Grade Gliomas: Association with Prognosis
dc.typeMakale
dc.relation.journalNOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
dc.contributor.departmentİstanbul Teknik Üniversitesi , ,
dc.identifier.volume58
dc.identifier.issue2
dc.identifier.startpage133
dc.identifier.endpage136
dc.contributor.firstauthorID2686287


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster